» Articles » PMID: 34874934

Prediction of Post Transarterial Chemoembolization MR Images of Hepatocellular Carcinoma Using Spatio-temporal Graph Convolutional Networks

Overview
Journal PLoS One
Date 2021 Dec 7
PMID 34874934
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Magnetic resonance imaging (MRI) plays a critical role in the planning and monitoring of hepatocellular carcinomas (HCC) treated with locoregional therapies, in order to assess disease progression or recurrence. Dynamic contrast-enhanced (DCE)-MRI sequences offer temporal data on tumor enhancement characteristics which has strong prognostic value. Yet, predicting follow-up DCE-MR images from which tumor enhancement and viability can be measured, before treatment of HCC actually begins, remains an unsolved problem given the complexity of spatial and temporal information. We propose an approach to predict future DCE-MRI examinations following transarterial chemoembolization (TACE) by learning the spatio-temporal features related to HCC response from pre-TACE images. A novel Spatial-Temporal Discriminant Graph Neural Network (STDGNN) based on graph convolutional networks is presented. First, embeddings of viable, equivocal and non-viable HCCs are separated within a joint low-dimensional latent space, which is created using a discriminant neural network representing tumor-specific features. Spatial tumoral features from independent MRI volumes are then extracted with a structural branch, while dynamic features are extracted from the multi-phase sequence with a separate temporal branch. The model extracts spatio-temporal features by a joint minimization of the network branches. At testing, a pre-TACE diagnostic DCE-MRI is embedded on the discriminant spatio-temporal latent space, which is then translated to the follow-up domain space, thus allowing to predict the post-TACE DCE-MRI describing HCC treatment response. A dataset of 366 HCC's from liver cancer patients was used to train and test the model using DCE-MRI examinations with associated pathological outcomes, with the spatio-temporal framework yielding 93.5% classification accuracy in response identification, and generating follow-up images yielding insignificant differences in perfusion parameters compared to ground-truth post-TACE examinations.

Citing Articles

Advancements in Artificial Intelligence-Enhanced Imaging Diagnostics for the Management of Liver Disease-Applications and Challenges in Personalized Care.

Nishida N Bioengineering (Basel). 2025; 11(12.

PMID: 39768061 PMC: 11673237. DOI: 10.3390/bioengineering11121243.


Artificial Intelligence and Machine Learning Predicting Transarterial Chemoembolization Outcomes: A Systematic Review.

Cho E, Law M, Yu Z, Yong J, Tan C, Tan E Dig Dis Sci. 2024; 70(2):533-542.

PMID: 39708260 DOI: 10.1007/s10620-024-08747-5.

References
1.
Abajian A, Murali N, Savic L, Laage-Gaupp F, Nezami N, Duncan J . Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept. J Vasc Interv Radiol. 2018; 29(6):850-857.e1. PMC: 5970021. DOI: 10.1016/j.jvir.2018.01.769. View

2.
Cook G, OBrien M, Siddique M, Chicklore S, Loi H, Sharma B . Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis. Radiology. 2015; 276(3):883-93. DOI: 10.1148/radiol.2015141309. View

3.
Braman N, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P . Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 2017; 19(1):57. PMC: 5437672. DOI: 10.1186/s13058-017-0846-1. View

4.
Voizard N, Cerny M, Assad A, Billiard J, Olivie D, Perreault P . Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging. 2019; 10(1):121. PMC: 6920285. DOI: 10.1186/s13244-019-0801-z. View

5.
Nie K, Shi L, Chen Q, Hu X, Jabbour S, Yue N . Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI. Clin Cancer Res. 2016; 22(21):5256-5264. PMC: 10916000. DOI: 10.1158/1078-0432.CCR-15-2997. View